Research Article
Retrospective Evaluation of COVID-19 Therapeutics
@INPROCEEDINGS{10.1007/978-3-031-23902-1_29, author={Yuhan Gao and Zunjie Zhu and Yaoqi Sun and Dongmei Yu and Peiwu Qin and Cai Cheng and Ming Xu and Yuhan Dong and Jiyong Zhang and Mang Xiao}, title={Retrospective Evaluation of COVID-19 Therapeutics}, proceedings={Mobile Multimedia Communications. 15th EAI International Conference, MobiMedia 2022, Virtual Event, July 22-24, 2022, Proceedings}, proceedings_a={MOBIMEDIA}, year={2023}, month={2}, keywords={COVID-19 Therapeutics Single-center retrospective observational study}, doi={10.1007/978-3-031-23902-1_29} }- Yuhan Gao
Zunjie Zhu
Yaoqi Sun
Dongmei Yu
Peiwu Qin
Cai Cheng
Ming Xu
Yuhan Dong
Jiyong Zhang
Mang Xiao
Year: 2023
Retrospective Evaluation of COVID-19 Therapeutics
MOBIMEDIA
Springer
DOI: 10.1007/978-3-031-23902-1_29
Abstract
The pandemic outbreak of COVID-19 created panic all over the world. As therapeutics that can effectively wipe out the virus and terminate transmission are not available, supportive therapeutics are the main clinical treatments for COVID-19. Repurposing available therapeutics from other viral infections is the primary surrogate in ameliorating and treating COVID-19. The therapeutics should be tailored individually by analyzing the severity of COVID-19, age, gender, comorbidities, and so on. We aim to investigate the effects of COVID-19 therapeutics and to search for laboratory parameters indicative of severity of illness. Multi-center collaboration and large cohort of patients will be required to evaluate therapeutics combinations in the future.
This study is a single-center retrospective observational study of COVID-19 clinical data in China. Information on patients’ treatment modalities, previous medical records, individual disease history, and clinical outcomes were considered to evaluate treatment efficacy. After screening, 2,844 patients are selected for the study. The result shows that treatment with TCM (Hazard Ratio (HR) 0.191 [95% Confidence Interval (CI), 0.14–0.25]; p < 0.0001), antiviral therapy (HR 0.331 [95% CI 0.19–0.58]; p = 0.000128), or Arbidol (HR 0.454 [95% CI 0.34–0.60]; p < 0.0001) is associated with good prognostic of patients. Multivariate Cox regression analysis showed TCM treatment decreased the mortality hazard ratio by 69.4% (p < 0.0001).
